Ironwood Pharmaceuticals, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; interim financial statements are unaudited. Unless noted, amounts are in U.S. dollars.
Business context
Ironwood is a clinical-stage pharmaceutical company focused on human therapeutics. Its lead candidate, linaclotide, was under U.S. FDA review for IBS-C and chronic constipation; the company had no product sales. Revenue came from collaborations and licensing arrangements with Forest, Almirall and Astellas. Linaclotide’s NDA was submitted with Forest, and Almirall’s European application remained under review.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Collaborative arrangements revenue | $12.2 million | $10.2 million; up 19.6% |
| Research and development expense | $29.5 million | $19.6 million; up 50.9% |
| General and administrative expense | $18.4 million | $9.2 million; up 99.2% |
| Total operating expenses | $47.9 million | $28.8 million; up 66.4% |
| Operating loss | $35.6 million | $18.5 million |
| Net loss | $35.6 million; $0.34 per share | $18.4 million; $0.19 per share |
| Operating cash used | $43.1 million | $23.9 million |
| Cash and cash equivalents, March 31 | $131.6 million | $87.3 million at December 31, 2011 |
| Available-for-sale securities, March 31 | $70.5 million | $76.7 million at December 31, 2011 |
Operating and net losses were each approximately 291% of revenue; the filing reports no product gross margin. Unrestricted cash, cash equivalents and securities totaled about $202.1 million. Current assets were $206.3 million versus current liabilities of $52.3 million. Capital lease obligations totaled approximately $0.7 million; the filing reports no material conventional debt balance. Stockholders’ equity was $164.1 million, and accumulated deficit was $468.0 million.
Changes and notable items
- Revenue rose by $2.0 million, primarily reflecting an estimated $2.1 million of additional Almirall revenue from a prior-period revision to the expected development period.
- R&D expense increased by $10.0 million, including higher staffing, non-linaclotide collaboration costs, linaclotide costs and facility expense. G&A increased by $9.2 million, driven by staffing, commercialization preparation, facilities and Forest-related commercial activity.
- In February 2012, Ironwood issued 6,037,500 Class A shares and received approximately $85.2 million net. Financing cash flow was $86.1 million, contributing to a $44.3 million increase in cash during the quarter.
- Q1 results included $3.0 million paid upfront for the Bionomics BNC210 collaboration and increased commercial-preparation spending. The company also reported $3.3 million of Q1 R&D expense associated with that agreement.
Outlook, risks and contingencies
- In April 2012, the FDA extended its review period for linaclotide by three months; the PDUFA target action date moved to September 2012. No advisory committee meeting was planned. Approval and commercial launch remained uncertain.
- Management expected substantial losses to continue for several years and projected that available resources, together with potential collaboration milestones, would support operations through anticipated commercialization. This is a forward-looking estimate; actual needs could differ. Ironwood expected an $85 million Forest milestone upon FDA approval, contingent on approval.
- The company reported approximately $58.7 million in minimum linaclotide supply purchase commitments through 2017, including $16.5 million for the remaining nine months of 2012.
- Key risks include regulatory delay or denial, adverse effects, manufacturing capacity and quality, dependence on collaboration partners, market adoption and reimbursement, competition, and the need for additional funding. Diarrhea was the most common reported adverse event in linaclotide Phase 3 trials; it occurred in 14%–20% of treated patients and led to discontinuation in 3%–6%.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. It did not expect ordinary-course litigation or indemnification matters to have a material adverse effect; no material related claims were outstanding.
Important facts for investors to verify
- FDA review status and outcome, including whether the September 2012 target date changed and whether both proposed indications and desired labeling were approved.
- Cash use and runway against the $202.1 million liquid-resource balance, ongoing losses and commercialization costs.
- Whether the $85 million Forest approval milestone was achieved and how collaboration economics and any launch costs affect future cash flows.
- Execution of manufacturing commitments, commercial supply readiness and the company’s ability to meet the disclosed minimum purchases.
- Progress in Europe and Asia, partner performance, and the potential impact of reimbursement, competition and linaclotide’s safety profile.